|
|
|
Welcome to MyelomaLinks,
your monthly source of myeloma news,
research updates, clinical trials
and events of The Leukemia & Lymphoma
Society (LLS). For even more information,
regularly visit our Patient
Services and Disease
Information Web
sections. | |
 |
|
|
|
LLS
Features
::READ MORE::
.....................................................................................................................................
Research
Roundup ::READ MORE::
.....................................................................................................................................
IRC Question of
the Month
:: READ
MORE::
| |
|
Inspirational
Stories
 Learn
how individuals touched by blood cancer
cope. LLS's LifeMosaic
Web feature offers hundreds of
inspiring stories by patients and families. Read
them or submit
your own.
|
Here to
Help
For even more information, regularly
visit the LLS Web site, www.LLS.org, where many of our education programs
are archived free of charge for convenient
access 24/7.
If you haven't found what
you're looking for in MyelomaLinks ,
please call our Information Resource Center
(IRC) to speak with trained information
specialists. IRC staff are available Monday
through Friday, 9 a.m. to 6 p.m. ET, toll free
at (800) 955-4572; email infocenter@lls.org; or click the "Live Patient Help" button
on the www.LLS.org homepage.
In this new
year, please consider a tax-deductible gift to
LLS. Donate
online today and help us make
a difference in the lives of patients and their
families. | |
|
|
Commentary
LLS's
Deborah Banker, Ph.D., discusses
some of the latest innovations presented at the
recent American Society of Hematology annual
meeting.
Clinical Trials
We invite you to
use our LLS-supported
TrialCheck® Web site
, a clinical trial search service that
offers patients and caregivers immediate access
to listings of all myeloma clinical trials.
Answer just a few simple questions and a list of
available clinical trials related to your cancer
will appear in an easy-to-read list of search
results.
You may also want to
visit the National Cancer Institute's Cancer
Trials Support Unit, providing resources
and information on Phase III cancer treatment
trials supported by the National Cancer
Institute. ::SELECTED TRIALS::
Newsfeeds &
Podcasts
Now
you can get RSS Feeds and Podcasts from LLS.
:: CLICK HERE TO SIGN
UP::
Free
eNewsletters
Free LLS
eNewsletters deliver the latest information on
research and treatment options, patient services
programs and fundraising events.
::CLICK HERE TO SIGN
UP::
| | | |
| 
| | | |
|
|
|
Milestones
in Myeloma Therapy: An Update from the American
Society of Hematology Annual
Meeting
Register online for this free
telephone education program on Tuesday, Feb. 3,
1 p.m. - 2:30 p.m. ET. The guest speaker
is Robert Orlowski, M.D., Ph.D.,
director, Myeloma Section, associate professor,
Departments of Lymphoma/Myeloma and Experimental
Therapeutics, Division of Cancer
Medicine, The University of Texas M.D.
Anderson Cancer Center. Participants will have the opportunity to
ask Dr. Orlwowski questions during the
program.
Co-Pay
Assistance Program
Patients with
myeloma who have difficulty paying for or
simply cannot afford their prescription drug
co-pays or health insurance premiums can now
apply for up to $5,000 in assistance from
LLS.
LLS
Advocacy
LLS's advocacy team
represents the needs of cancer patients and
their families in Washington, DC
and state capitals throughout the United
States. We need your help. Join our Advocates
Network and make your voice
heard. Act Now! Urge
Your Representative to Join the Pediatric Cancer
Caucus.
The Leukemia & Lymphoma
Society is committed to curing blood cancers and
helping patients and their families. Learn
the many ways you can help advance
LLS's mission.
> Back to the
top
| |
|
A systematic review of
Phase II trials of thalidomide/dexamethasone
combination therapy in patients with relapsed or
refractory multiple myeloma ::READ MORE::
Treatment of newly
diagnosed myeloma ::READ MORE::
Bortezomib is
associated with better health-related quality of
life than high-dose dexamethasone in patients
with relapsed multiple myeloma: results from the
APEX study ::READ MORE::
A prospective PETHEMA
study of tandem autologous transplantation
versus autograft followed by reduced-intensity
conditioning allogeneic transplantation in newly
diagnosed multiple myeloma ::READ MORE::
> Back to the
top | |
Selected
Trials
Phase II: Bortezomib,
Thalidomide and Dexamethasone after Melphalan
and Stem Cell Transplant in Treating Patients
with Stage I, II or III Multiple
Myeloma ::READ MORE::
Phase 1/2 Study of Monoclonal
Antibody to Treat Multiple Myeloma ::READ MORE::
Phase IV: Lenalidomide and
Dexamethasone with/without Transplant in
Patients with Multiple Myeloma ::READ MORE::
Trial of Romidepsin and
Bortezomib for Multiple Myeloma ::READ MORE::
A Study of Sativex for Pain
Relief in Patients with Advanced
Malignancy ::READ MORE::
> Back to the
top | |
IRC Question of
the Month
| 
Q: At what age is a
patient not eligible for a clinical trial?
A: All clinical trials have
eligibility guidelines. These guidelines may be
based on the patient's age, the type and stage
of disease, previous treatment history and any
co-existing medical conditions; for example,
diabetes or high blood pressure.
Guidelines are sometimes called "inclusion
criteria" (the characteristics of patients who
may take part in the trial) and "exclusion
criteria" (the characteristics of patients who
cannot take part in the trial). Inclusion and
exclusion criteria are used to ensure that
patient participation is appropriate for the
goals of the trial and to produce reliable
medical research results.
Some older patients may assume clinical
trials are not for them. This is not necessarily
true. Studies have shown that age alone does not
reflect a person's overall health and ability to
benefit from a clinical trial. Many older adults
have been treated successfully in clinical
trials. According to reports, overall,
patients in clinical trials receive more
follow-up care and better disease and
side-effect management, compared
with patients receiving treatment outside
of clinical trial settings.
Nationwide participation in clinical trials
by older adults is growing. Participation
across age-groups helps doctors determine if a
treatment is safe and effective for people of
different ages. Some trials are not appropriate
for older adults or a subgroup of older adults,
such as those with serious medical
complications. But more trials are being offered
to older adults, and there are also trials
designed specifically for them.
It is important to discuss clinical trials as
an option with your doctor. Please also
contact LLS's Information Resource
Center (IRC) at ( 800) 955-4572 to
find out more about clinical trials and other
treatment options for older adults
with myeloma. You may also order the free
LLS booklet Understanding
Clinical Trials for Blood Cancers
.
As always, we encourage
patients, their families and caregivers to turn
to the IRC for information and support. IRC
specialists are available 9 a.m. to 6 p.m. ET.
Call us with your questions at (800)
955-4572.
> Back to the
top | |
| | | |
|
|
 |
Supported by an
unrestricted
educational grant
from
 |
 |
|
Contact Us: The
Leukemia & Lymphoma Society, 1311 Mamaroneck
Ave., White Plains, NY 10605, (800)
955-4572
|
|
| Visit our e-Store
& Special Offers page where you can
support businesses that support
LLS. | | | | | |
|
| | | |
